Omega MonoPure 1300 EC 120 sg

Omega MonoPure 1300 EC 120 sg by Xymogen

Omega MonoPure 1300 EC 120 softgels is a product formulated by Xymogen with a naturally enhanced form of fish oil: MaxSimil® monoglyceride fish oil.* It is an enzyme-enriched type of oil that may have up to three times higher absorption rate than traditional fish oil products.* This makes Omega MonoPure 1300 EC 120sg stand out among cardiovascular supplements, turning it into a popular prescription choice among healthcare practitioners.*

Who May Benefit from Taking Omega MonoPure 1300 EC 120 Softgels?

Omega MonoPure 1300 EC 120 softgels may support your health if you:

• want to improve your general health and wellness*
• don’t consume fish in your diet*
• prefer easy-to-swallow supplements*

Omega MonoPure 1300 EC 120sg—Effects?

Omega MonoPure 1300 EC 120sg may potentially:

• improve the production of arachidonic acid-derived eicosanoids*
• support cardiovascular health
• support cognitive health
• support glucose and insulin metabolism*
• promote healthy lipid function*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. To learn more about this product, book a FREE supplement consultation at Covenant Health Products.

Recommendation:
Xymogen suggests taking one Omega MonoPure 1300EC softgel daily, or use as directed by your healthcare practitioner.

Serving Size: 1 Softgel
Servings Per Container: 120

Amount Per Serving:
Calories 10
Total Fat 1 g
MaxSimil Fish Oil Concentrate 1.3 g
Total Omega-3 Fatty Acids 860 mg
EPA (eicosapentaenoic acid) 600 mg
DHA (docosahexaenoic acid) 260 mg

Other Ingredients: Softgel (fish gelatin, vegetable glycerin, and purified water), GRAS enteric coating (ethylcellulose, sodium alginate, purified water, medium-chain triglycerides, oleic acid, vegetable stearic acid, and ammonium hydroxide), and mixed natural tocopherols.

Storage:
Keep closed in a cool, dry place out of reach of children. Variations in temperature may cloud the softgels. This does not affect the formula’s efficacy or safety. Do not refrigerate.

Contains:
Fish (anchovy and/or sardine [sources of fish oil], tilapia and/or pangasius [sources of fish gelatin]).

Does Not Contain: Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified.

Trademarks:
Manufactured using MaxSimil® fish oil. MaxSimil® is a registered trademark of Ingenutra Inc. Protected under US patents 8,119,690 and 8,198,324; Canadian patents 2672513 and 2677670.

IFOS™ certification mark is a registered trademark of Nutrasource Diagnostics Inc.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

 Click here to view Data Sheet

LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518

References:

1. Bogani, P., Galli, C., Villa, M., et al. (2007). Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis, 190(1), 181–186. [PMID: 16488419]
2. Castañer, O., Covas, M. I., Khymenets, O., et al. (2012). Protection of LDL from oxidation by olive oil polyphenols is associated with a downregulation of CD40-ligand expression and its downstream products in vivo in humans. American Journal of Clinical Nutrition, 95(5), 1238–1244. [PMID: 22440854]
3. Chiva-Blanch, G., Badimon, L., & Estruch, R. (2014). Latest evidence of the effects of the Mediterranean diet in prevention of cardiovascular disease. Current Atherosclerosis Reports, 16(10), 446. [PMID: 25115436]
4. Fitó, M., Cladellas, M., de la Torre, R., et al. (2008). Anti-inflammatory effect of virgin olive oil in stable coronary disease patients: A randomized, crossover, controlled trial. European Journal of Clinical Nutrition, 62(4), 570–574. [PMID: 17375118]
5. Fortin, S., inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. (2012). Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof. US Patent 8,198,324. June 12, 2012.
6. Fortin, S., inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. (2012). Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US Patent 8,119,690. February 21, 2012.
7. Fortin, S., inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. (2012). Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US Patent 8,329,747. December 11, 2012.
8. Gimeno, E., de la Torre-Carbot, K., Lamuela-Raventós, R. M., et al. (2007). Changes in the phenolic content of low-density lipoprotein after olive oil consumption in men: A randomized crossover controlled trial. British Journal of Nutrition, 98(6), 1243–1250. [PMID: 17617938]
9. Guasch-Ferré, M., Hu, F. B., Martínez-González, M. A., et al. (2014). Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED Study. BMC Medicine, 12, 78. [PMID: 24886626]
10. Guasch-Ferré, M., Hu, F. B., Martínez-González, M. A., et al. (2013). Primary prevention of cardiovascular disease with a Mediterranean diet. New England Journal of Medicine, 368(14), 1279–1290. [PMID: 23432189]
11. Mayor, S. (2016). Mediterranean diet reduces cardiovascular events in people with heart disease, study shows. BMJ, 353, i2348. [PMID: 27114468]
12. MaxSimil Patented Lipid Absorption Technology Clinical Study Report: MaxSimil® 3020 Omega-3. (2015). Sherbrooke, Québec, Canada: Ingenutra. [Unpublished, internal data]
13. Morin, C., Blier, P. U., & Fortin, S. (2015). Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model. Arthritis Research & Therapy, 17, 142. [PMID: 26022389]
14. Morin, C., Fortin, S., Cantin, A. M., et al. (2011). Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: Implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. American Journal of Respiratory Cell and Molecular Biology, 45(2), 366–375. [PMID: 21057106]
15. Morin, C., Fortin, S., Rousseau, É. (2012). New omega-3 derivatives reduce airway inflammation and prevent rho-kinase activation in an allergic model of asthma. Journal of Allergy & Therapy, 3(S1), 003. doi:10.4172/2155-6121.S1-003.
16. Morin, C., Rousseau, É., & Blier, P. U. (2015). Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 309(1), H93–H102. [PMID: 25910811]
17. Morin, C., Rousseau, É., Cantin, A. M., et al. (2013). MAG-EPA resolves lung inflammation in an allergic model of asthma. Clinical & Experimental Allergy, 43(9), 1071–1082. [PMID: 23957343]
18. Raederstorff, D. (2009). Antioxidant activity of olive polyphenols in humans: A review. International Journal of Vitamin and Nutrition Research, 79(3), 152–165. [PMID: 20209466]
19. Ruano, J., López-Miranda, J., de la Torre, R., et al. (2007). Intake of phenol-rich virgin olive oil improves the postprandial prothrombotic profile in hypercholesterolemic patients. American Journal of Clinical Nutrition, 86(2), 341–346. [PMID: 17684203]
20. Weylandt, K. H., Chiu, C. Y., Gomolka, B., et al. (2012). Omega-3 fatty acids and their lipid mediators: Towards an understanding of resolving and protecting formation. Prostaglandins & Other Lipid Mediators, 97(3-4), 73–82. [PMID: 22326554]